Hydroxyapatite for Dental Caries

Possibly, but unproven: fluoride-free hydroxyapatite toothpaste was not significantly worse than fluoride toothpaste at limiting cavities (dental caries) in three small trials, but none showed it better, so it should not replace fluoride, especially for children or people prone to cavities. The trials: in children (Paszynska 2021, 207 children, 336 days), adults (Paszynska 2023, 189 adults, 18 months) and orthodontic patients (Schlagenhauf 2019, 150 patients, 168 days), caries progression was similar with fluoride-free hydroxyapatite and with fluoride toothpaste.

Reviews of the wider hydroxyapatite literature disagree. A 2021 meta-analysis of three RCTs called the evidence good; a 2022 review of nano-hydroxyapatite studies rated it very low certainty and not conclusive. Fluoride's evidence is far larger (96 studies in the 2019 Cochrane review), so this page rates hydroxyapatite as promising but unproven for cavity prevention, and not a reason to drop fluoride, particularly for children and people who get cavities easily.

Enamel is mostly hydroxyapatite. The idea behind the toothpaste is that hydroxyapatite particles help re-harden early enamel lesions (remineralization) and slow acid damage (demineralization). A 2025 meta-analysis of four randomized trials (described as in situ) in people under 25 found hydroxyapatite and fluoride toothpastes differed significantly in lesion size (p < 0.0001) and fluorescence (p = 0.01) after 6 months; the abstract does not say which toothpaste did better.

The same review found no significant difference in new or progressing lesions (recorded with DMFS/ICDAS indices) between the two (risk ratio 0.98, 95% CI 0.85 to 1.12), so the lesion-size and fluorescence differences were not matched by a difference in how many lesions developed or progressed.

In situ results are mixed. A 2022 review found that under demineralizing conditions sodium fluoride hindered mineral loss and nano-hydroxyapatite did not; under remineralizing conditions both had the same remineralizing potential. The authors graded the evidence very low and noted six studies were funded or published by the manufacturers.

Hardness, lesion size and fluorescence are proxies. Trials counting new lesions in people, over a year or more, show whether it matters for cavities.

There is no established dose. The trials gave a toothpaste, not a measured amount: children brushed three times daily in both the 1-year and the 2-year trials, and the 2-year trial specified 2 minutes each time. The abstracts for the adult and orthodontic trials do not report brushing frequency or the hydroxyapatite concentration, so this page does not either.

Products differ in whether they contain fluoride, which changes what the trials tell you.

In 207 children (analysis of the primary teeth), caries (ICDAS code 1 or higher) increased in 72.7% of the hydroxyapatite group (n = 88) and 74.2% of the fluoride group (n = 89). The upper 95% confidence limit for the difference was 9.8% against a non-inferiority margin of 20%.

In 189 adults over 18 months, no increase in the DMFS index (decayed, missing and filled surfaces) occurred in 89.3% of the hydroxyapatite group and 87.4% of the fluoride group (per-protocol, 171 completers). In 150 orthodontic patients, enamel caries increased in 56.8% (ITT) of the hydroxyapatite group and 60.9% of the fluoride group, with no significant difference.

A 2-year triple-blind trial compared toothpastes with fluoride-substituted hydroxyapatite (1000 or 1450 ppm fluoride) against monofluorophosphate toothpastes in 610 Italian schoolchildren (518 finished). Caries increment for severe lesions was lower in the hydroxyapatite arms: 0.18 vs 0.27 (P = 0.04) in the younger children and 0.16 vs 0.30 (P = 0.01) in the older ones. In permanent teeth it was also lower (initial lesions 0.09 vs 0.17, P = 0.02).

A second report with an identical design (apparently the same trial) found 58 of 78 active lesions in the hydroxyapatite arm had become inactive, with a significant difference in primary teeth (P = 0.04). Because both pastes contained fluoride, this does not show that fluoride-free hydroxyapatite works.

A 2024 review pooled 5 clinical and 8 in situ trials; its commentary reports a pooled odds ratio of 2.51 favouring hydroxyapatite over placebo toothpaste and 1.1 against fluoride toothpaste (not significant). A 2025 meta-analysis of four randomized trials found no significant difference in lesion development (RR 0.98).

A 2022 review judged the evidence not conclusive: few clinical studies, short follow-up, high risk of bias, and six studies funded or published by manufacturers. The 2024 review's authors, whose names overlap with those of the 2021 and 2026 reviews, conclude hydroxyapatite is effective without fluoride and an ideal substitute in toothpaste for young children. A 2024 white spot lesion meta-analysis found nano-hydroxyapatite improved enamel hardness more than fluoride alone (MD 9.29), but 10 of its 14 studies were laboratory studies and there was no colour improvement.

Independent replication. The 2021 child trial, the 2023 adult trial and the 2024 review share authors (Paszynska, Pawinska; the 2023 trial and 2024 review also Enax, Meyer, Amaechi, Limeback). The 2019 orthodontic trial shares Schlagenhauf and May with the 2021 trial. Enax is an author of the 2021 meta-analysis, the 2023 trial, the 2024 review and the 2026 review; Amaechi is an author of the 2021 child trial, the 2023 trial, the 2024 review and the 2026 review.

Nothing beyond 24 months, no separate reporting of fillings or tooth loss beyond composite scores such as DMFS, and no head-to-head superiority trial of a fluoride-free paste. The child and adult trials allowed a 20 percentage-point margin (the orthodontic abstract reports none), wide enough that a clinically relevant gap could hide inside it.

The trials' abstracts did not highlight adverse effects, and the authors of the adult trial concluded hydroxyapatite was a safe and efficient anticaries agent. The EU Scientific Committee on Consumer Safety (2025) judged hydroxyapatite (nano) safe up to 29.5% in toothpaste and 10% in mouthwash, citing no mutagenic, cytotoxic or inflammatory effect in a mouth-lining cell model and rapid dissolution of swallowed particles in stomach fluid.

That opinion covers only uncoated rod-shaped particles up to about 122 nm long (122 ± 43 nm) with limited aspect ratios, and excludes needle-shaped particles. The child and orthodontic fluoride-free trials used microcrystalline hydroxyapatite (the adult abstract does not specify), so the opinion does not directly describe them. The real risk to weigh is giving up fluoride: the 2019 Cochrane review found 1000 to 1250 ppm fluoride toothpaste reduced caries in children and adolescents (SMD -0.28, 95% CI -0.32 to -0.25) with high-certainty evidence, while higher concentrations raise the risk of fluorosis in young children.

Hydroxyapatite toothpaste is a topical product. The sources read did not report drug interactions. The questions are about how it fits with the other caries tools.